US 12,065,509 B2
Substances and methods for the use in prevention and/or treatment in huntingon's disease
Oskar Smrzka, Vienna (AT); Stefan Bartl, Vienna (AT); and Michela Parth, Vienna (AT)
Assigned to HD IMMUNE GMBH, Vienna (AT)
Filed by HD IMMUNE GMBH, Vienna (AT)
Filed on Nov. 5, 2021, as Appl. No. 17/520,141.
Application 17/520,141 is a division of application No. 16/996,031, filed on Aug. 18, 2020, abandoned.
Application 16/996,031 is a continuation of application No. 16/025,095, filed on Jul. 2, 2018, abandoned.
Application 16/025,095 is a continuation of application No. 15/323,461, granted, now 10,053,518, issued on Aug. 21, 2018, previously published as PCT/EP2015/065795, filed on Jul. 10, 2015.
Claims priority of application No. 14176609 (EP), filed on Jul. 10, 2014.
Prior Publication US 2022/0073650 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 17/02 (2006.01); C07K 16/18 (2006.01); G01N 33/577 (2006.01); G01N 33/68 (2006.01)
CPC C07K 17/02 (2013.01) [C07K 16/18 (2013.01); G01N 33/577 (2013.01); G01N 33/6896 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); G01N 2800/2835 (2013.01)] 3 Claims
 
1. A monoclonal antibody having a binding domain that binds to a peptide of the Huntingtin (HTT) protein having the sequence of p7543 (SEQ ID No. 3) and
wherein the monoclonal antibody comprises a heavy chain variable region CDR1 comprising GYTFTEYT (SEQ ID No. 66), a heavy chain variable region CDR2 comprising INPNNGGT (SEQ ID No. 67), a heavy chain variable region CDR3 comprising ASLDGRDY (SEQ ID No. 68), a light chain variable region CDR1 comprising QSLLNSRTRKNY SEQ ID No. 69), a light chain variable region CDR2 comprising WASX (SEQ ID No. 70) and a light chain variable region comprising KQSYNLLT (SEQ ID No. 71); or
wherein the monoclonal antibody comprises a light chain variable region comprising SEQ ID NO:97 and a heavy chain variable region comprising SEQ ID NO:98.